PRT811 Showcases Early Signals of Efficacy in IDH-Mutant Glioma and Uveal Melanoma
OncLive,
Varun Monga, MBBS Phase 1 research indicates that continued investigation with the protein arginine methyltransferase 5 (PRMT5…
Abstract P044: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade…
Overview of attention for article published in Molecular Cancer Therapeutics, December 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (77th percentile)
-
High Attention Score compared to outputs of the same age and source (86th percentile)
Readers on
- mendeley
- 2 Mendeley